20 citations
,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
4 citations
,
January 2007 in “Iraqi postgraduate Medical Journal”
2 citations
,
April 2012 in “Science-business Exchange” Blocking a protein called prostaglandin D2 might help treat hair loss.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
6 citations
,
February 2020 in “Journal of Natural Products” A new compound from a sponge strongly inhibits an enzyme linked to male-pattern hair loss without being toxic at low levels.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
191 citations
,
October 2012 in “International Current Pharmaceutical Journal” Solid lipid nanoparticles are promising for delivering various drugs and improving treatment effectiveness.
November 2024 in “International Journal of Scientific Reports” Dienogest is safer and has fewer side effects than GnRH analogues for treating endometriosis.
72 citations
,
January 2011 in “Current Pharmaceutical Design” S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
30 citations
,
October 2015 in “Journal of Ethnopharmacology” Herbal compounds like ricinoleic acid, quercetin-3-O-rutinoside, and hinokiflavone may be safe and effective for treating hair loss.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
Enzymatic synthesis improved the water solubility of the flavonoid baicalin, which may help treat hair loss conditions.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
January 2026 in “Journal of Dermatological Treatment” GT20029 showed some hair growth improvement, but longer studies are needed for better results.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
86 citations
,
November 2015 in “Journal of Gastroenterology” The NUDT15 R139C variant causes thiopurine-induced leukocytopenia through a different mechanism than previously thought in Japanese patients with inflammatory bowel disease.
December 2023 in “Journal of the Endocrine Society” Blocking glucocorticoid receptors improves glucose metabolism in a PCOS mouse model.
13 citations
,
November 2017 in “Neurotoxicity research/Neurotoxicity resarch” Sodium metabisulfite increases sodium channel activity, leading to higher cell excitability and potential damage.
4 citations
,
December 2021 in “Archivio italiano di urologia andrologia” Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
June 2026 in “The Journal of Steroid Biochemistry and Molecular Biology”
12 citations
,
December 2002 in “Fertility and Sterility” Spironolactone plus finasteride works better for treating hirsutism.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
4 citations
,
January 2020 in “Journal of family medicine and primary care” Increasing Teneligliptin on his own caused a man's hair loss, which stopped when he ceased the medication.
1 citations
,
March 2003 in “Journal of Investigative Dermatology” Early sunburn treatment with certain inhibitors may reduce skin cancer risk.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.